Renaissance Technologies (RenTech)'s ELDN Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 200,900 shares of Eledon Pharmaceuticals, Inc. (ELDN) worth $791,546, representing 0.00% of the portfolio. First purchased in 2021-Q1, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ELDN, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 176,300 shares. Largest reduction occurred in Q4 2025, reducing 172,210 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Eledon Pharmaceuticals (ELDN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eledon Pharmaceuticals (ELDN) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +176,300 | Add 716.67% | 200,900 | $3.94 |
| Q1 2026 | -152,390 | Reduce 86.10% | 24,600 | $3.08 |
| Q4 2025 | -172,210 | Reduce 49.32% | 176,990 | $1.51 |
| Q3 2025 | +158,527 | Add 83.14% | 349,200 | $2.59 |
| Q2 2025 | +67,900 | Add 55.31% | 190,673 | $2.71 |
| Q1 2025 | -24,400 | Reduce 16.58% | 122,773 | $3.39 |
| Q4 2024 | +11,300 | Add 8.32% | 147,173 | $4.12 |
| Q3 2024 | -900 | Reduce 0.66% | 135,873 | $2.49 |
| Q2 2024 | +49,704 | Add 57.09% | 136,773 | $2.64 |
| Q1 2024 | +17,896 | Add 25.87% | 87,069 | $2.06 |
| Q4 2023 | +7,200 | Add 11.62% | 69,173 | $1.81 |
| Q3 2023 | +1,600 | Add 2.65% | 61,973 | $1.37 |
| Q2 2023 | +28,200 | Add 87.65% | 60,373 | $0.00 |
| Q1 2023 | +2,500 | Add 8.43% | 32,173 | $0.00 |
| Q4 2022 | -2,200 | Reduce 6.90% | 29,673 | $0.00 |
| Q3 2022 | -300 | Reduce 0.93% | 31,873 | $2.76 |
| Q2 2022 | +13,700 | Add 74.16% | 32,173 | $2.46 |
| Q1 2022 | +4,800 | Add 35.11% | 18,473 | $3.95 |
| Q4 2021 | -25,990 | Reduce 65.53% | 13,673 | $4.39 |
| Q3 2021 | +18,556 | Add 87.91% | 39,663 | $6.18 |
| Q2 2021 | -5,944 | Reduce 21.97% | 21,107 | $7.91 |
| Q1 2021 | +27,051 | New Buy | 27,051 | $10.68 |
Renaissance Technologies (RenTech)'s Eledon Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Eledon Pharmaceuticals, Inc. (ELDN) in Q1 2021, acquiring 27,051 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Eledon Pharmaceuticals, Inc. (ELDN) for 22 quarters since Q1 2021.
Renaissance Technologies (RenTech)'s largest addition to Eledon Pharmaceuticals, Inc. (ELDN) was in Q2 2026, adding 200,900 shares worth $791,546.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 200,900 shares of Eledon Pharmaceuticals, Inc. (ELDN), valued at approximately $791,546.
As of the Q2 2026 filing, Eledon Pharmaceuticals, Inc. (ELDN) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Eledon Pharmaceuticals, Inc. (ELDN) was 349,200 shares, as reported at the end of Q3 2025.